Commonwealth Equity Services’s VYNE Therapeutics VYNE Stock Holding History

Commonwealth Equity Services’s Portfolio VYNE Stock Details VYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$10.9K	Hold	18,298	–	–	﹤0.01%	4277
2025 Q4	$10.6K	Hold	18,298	–	–	﹤0.01%	4262
2025 Q3	$6K	Hold	18,298	–	–	﹤0.01%	4229
2025 Q2	$30K	Hold	18,298	–	–	﹤0.01%	4201
2025 Q1	$29K	Hold	18,298	–	–	﹤0.01%	4107
2024 Q4	$61K	Hold	18,298	–	–	﹤0.01%	3969
2024 Q3	$34K	Buy	+18,298	New	+$34.7K	﹤0.01%	3966
2022 Q1	–	Sell	-1,106	Closed	-$20K	–	3809
2021 Q4	$20K	Hold	1,106	–	–	﹤0.01%	3601
2021 Q3	$27K	Buy	1,106 +68	+7%	+$2.64K	﹤0.01%	3535
2021 Q2	$65K	Hold	1,038	–	–	﹤0.01%	3443
2021 Q1	$127K	Sell	1,038 -34	-3%	-$4.93K	﹤0.01%	3233
2020 Q4	$122K	Sell	1,072 -371	-26%	-$46.6K	﹤0.01%	3033
2020 Q3	$172K	Hold	1,443	–	–	﹤0.01%	2774
2020 Q2	$179K	Buy	1,443 +66	+5%	+$8.94K	﹤0.01%	2643
2020 Q1	$265K	Buy	1,377 +29	+2%	+$9.1K	﹤0.01%	2156
2019 Q4	$450K	Buy	+1,348	New	+$449K	﹤0.01%	2000

Other funds holding VYNE

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return

Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

T3 Companies New York $76.8M AUM

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

KCA

KVP Capital Advisors San Francisco, California $134M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Commonwealth Equity Services's VYNE Position: Q1 2026 in Review

Commonwealth Equity Services held its VYNE Therapeutics (VYNE) position steady in Q1 2026 at 18,298 shares worth $10.9K. The position accounts for ﹤0.01% of the portfolio, ranked #4277.

Commonwealth Equity Services first reported a position in VYNE in Q4 2019 and has held it in 16 quarters since. The position peaked at $450K in Q4 2019. 45 funds tracked by Wall St. Rank hold VYNE as of Q1 2026.

Commonwealth Equity Services held 18,298 shares of VYNE Therapeutics worth $10.9K as of Q1 2026.
Commonwealth Equity Services left its VYNE Therapeutics share count unchanged in Q1 2026.
VYNE Therapeutics made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #4277 holding.
Commonwealth Equity Services first reported a position in VYNE Therapeutics in Q4 2019 and has held it in 16 quarters since.
Commonwealth Equity Services's VYNE Therapeutics position peaked at $450K in Q4 2019.
45 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q1 2026.

Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.